全文获取类型
收费全文 | 1696篇 |
免费 | 141篇 |
出版年
2023年 | 12篇 |
2022年 | 31篇 |
2021年 | 62篇 |
2020年 | 18篇 |
2019年 | 45篇 |
2018年 | 53篇 |
2017年 | 30篇 |
2016年 | 61篇 |
2015年 | 93篇 |
2014年 | 109篇 |
2013年 | 139篇 |
2012年 | 149篇 |
2011年 | 137篇 |
2010年 | 70篇 |
2009年 | 77篇 |
2008年 | 102篇 |
2007年 | 106篇 |
2006年 | 87篇 |
2005年 | 64篇 |
2004年 | 58篇 |
2003年 | 47篇 |
2002年 | 40篇 |
2001年 | 22篇 |
2000年 | 17篇 |
1999年 | 24篇 |
1998年 | 9篇 |
1997年 | 9篇 |
1996年 | 11篇 |
1995年 | 9篇 |
1994年 | 8篇 |
1993年 | 6篇 |
1992年 | 6篇 |
1991年 | 7篇 |
1990年 | 4篇 |
1989年 | 10篇 |
1988年 | 11篇 |
1987年 | 10篇 |
1986年 | 10篇 |
1985年 | 4篇 |
1983年 | 8篇 |
1982年 | 4篇 |
1981年 | 4篇 |
1980年 | 4篇 |
1979年 | 6篇 |
1978年 | 4篇 |
1976年 | 4篇 |
1974年 | 3篇 |
1973年 | 8篇 |
1972年 | 5篇 |
1970年 | 6篇 |
排序方式: 共有1837条查询结果,搜索用时 109 毫秒
101.
Salvatore Cozzolino Serena Aceto Paolo Caputo Luciano Gaudio Roberto Nazzaro 《Nordic Journal of Botany》1998,18(1):79-87
A chloroplast DNA restriction fragment length polymorphism analysis has been carried out on representatives species of Orchis (Orchidaceae) and of the allied genera Aceras, Dactylorhiza , and Anacamptis . One species of Cephalanthera and one of Serapias were used as outgroups. The consensus tree from a cladistic analysis showed that Orchis , as presently defined, is paraphyletic, as it contains also Aceras anthropophorum and Dactylorhiza saccifera . The genus Orchis is divided in two clades: one including O. laxiflora, O. papilionacea, O. coriophora , and O. morio in a ladderized sequence, the other showing D. saccifera at the base, followed by a clade in which a collapse of O. mascula, O. pauciflora, O. quadripunctata is sister group to a clade composed by O. italica, O. simia , and A. anthropophorum . These results, which agree to a great extent with literature evidence on chromosomes and isozymes, have been compared with various traditional systematic hypotheses for the genus. 相似文献
102.
Elisa Rossi Daniela Basso Carlo-Federico Zambon Filippo Navaglia Eliana Greco Michela Pelloso Serena Artuso Andrea Padoan Matilde Pescarin Ada Aita Dania Bozzato Stefania Moz Mara Cananzi Graziella Guariso Mario Plebani 《PloS one》2015,10(4)
Background
TNF-α and IFN-γ play a role in the development of mucosal damage in celiac disease (CD). Polymorphisms of TNFA and IFNG genes, as well as of the TNFRSF1A gene, encoding the TNF-α receptor 1, might underlie different inter-individual disease susceptibility over a common HLA risk background. The aims of this study were to ascertain whether five SNPs in the TNFA promoter (-1031T>C,-857C>T,-376G>A,-308G>A,-238G>A), sequence variants of the TNFRSF1A gene and IFNG +874A>T polymorphism are associated with CD in a HLA independent manner.Methods
511 children (244 CD, 267 controls) were genotyped for HLA, TNFA and INFG (Real Time PCR). TNFRSF1A variants were studied (DHPLC and sequence).Results
Only the rare TNFA-1031C (OR=0.65, 95% CI:0.44-0.95), -857T (OR=0.42, 95% CI:0.27-0.65), -376A (OR=2.25, 95% CI:1.12-4.51) and -308A (OR=4.76, 95% CI:3.12-7.26) alleles were significantly associated with CD. One TNFRSF1A variant was identified (c.625+10A>G, rs1800693), but not associated with CD. The CD-correlated TNFA SNPs resulted in six haplotypes. Two haplotypes were control-associated (CCGG and TTGG) and three were CD-associated (CCAG, TCGA and CCGA). The seventeen inferred haplotype combinations were grouped (A to E) based on their frequencies among CD. Binary logistic regression analysis documented a strong association between CD and HLA (OR for intermediate risk haplotypes=178; 95% CI:24-1317; OR for high risk haplotypes=2752; 95% CI:287-26387), but also an HLA-independent correlation between CD and TNFA haplotype combination groups. The CD risk for patients carrying an intermediate risk HLA haplotype could be sub-stratified by TNFA haplotype combinations.Conclusion
TNFA promoter haplotypes associate with CD independently from HLA. We suggest that their evaluation might enhance the accuracy in estimating the CD genetic risk. 相似文献103.
Carolina Serena Enrique Calvo Mari Paz Clares María Luisa Diaz Javier U. Chicote Raúl Beltrán-Debon Ramón Fontova Alejandro Rodriguez Enrique García-Espa?a Antonio García-Espa?a 《PloS one》2015,10(3)
Background
The clinical use of purified SOD enzymes has strong limitations due to their large molecular size, high production cost and immunogenicity. These limitations could be compensated by using instead synthetic SOD mimetic compounds of low molecular weight.Background/Methodology
We have recently reported that two SOD mimetic compounds, the MnII complexes of the polyamines Pytren2Q and Pytren4Q, displayed high antioxidant activity in bacteria and yeast. Since frequently molecules with antioxidant properties or free-radical scavengers also have anti-inflammatory properties we have assessed the anti-inflammatory potential of Pytren2Q and Pytren4Q MnII complexes, in cultured macrophages and in a murine model of inflammation, by measuring the degree of protection they could provide against the cellular injury produced by lipopolisacharide, a bacterial endotoxin.Principal Findings
In this report we show that the MnII complex of Pytren4Q but not that of Pytren2Q effectively protected human cultured THP-1 macrophages and whole mice from the inflammatory effects produced by LPS. These results obtained with two molecules that are isomers highlight the importance of gathering experimental data from animal models of disease in assessing the potential of candidate molecules.Conclusion/Significance
The effective anti-inflammatory activity of the MnII complex of Pytren4Q in addition to its low toxicity, water solubility and ease of production would suggest it is worth taking into consideration for future pharmacological studies. 相似文献104.
Elena Turola Salvatore Petta Ester Vanni Fabiola Milosa Luca Valenti Rosina Critelli Luca Miele Livia Maccio Vincenza Calvaruso Anna L. Fracanzani Marcello Bianchini Nazarena Raos Elisabetta Bugianesi Serena Mercorella Marisa Di Giovanni Antonio Craxì Silvia Fargion Antonio Grieco Calogero Cammà Franco Cotelli Erica Villa 《Disease models & mechanisms》2015,8(9):1037-1046
105.
Cinzia Scambi Sara Ugolini T. Sakari Jokiranta Lucia De Franceschi Oscar Bortolami Valentina La Verde Patrizia Guarini Paola Caramaschi Viviana Ravagnani Guido Martignoni Chiara Colato Serena Pedron Fabio Benedetti Marco Sorio Fabio Poli Domenico Biasi 《PloS one》2015,10(2)
ObjectiveThe role of complement system in the pathogenesis of systemic sclerosis (SSc) has been debated during the last decade but an evident implication in this disease has never been found. We carried out an explorative study on SSc patients to evaluate the expression of soluble and local C5b-9 complement complex and its relation with a complement regulator, the Membrane Cofactor Protein (MCP, CD46) on skin vascular bed as target distinctive of SSc disease. We also analyzed two polymorphic variants in the complement activation gene cluster involving the MCP region.MethodsC5b-9 plasma levels of SSc patients and healthy subjects were analyzed by ELISA assay. Archival skin biopsies of SSc patients and controls were subjected to immunofluorescence analysis to detect C5b-9 and MCP on vascular endothelial cells. The expression of MCP was validated by immunoblot analysis with specific antibody. Polymorphic variants in the MCP gene promoter were tested by a quantitative PCR technique-based allelic discrimination method.ResultsEven though circulating levels of C5b-9 did not differ between SSc and controls, C5b-9 deposition was detected in skin biopsies of SSc patients but not in healthy subjects. MCP was significantly lower in skin vessels of SSc patients than in healthy controls and was associated with the over-expression of two polymorphic variants in the MCP gene promoter, which has been related to more aggressive phenotypes in other immune-mediated diseases.ConclusionsOur results firsty document the local complement activation with an abnormal expression of MCP in skin vessels of SSc patients, suggesting that a subset of SSc patients might be exposed to more severe organ complications and clinical evolution due to abnormal local complement activation. 相似文献
106.
107.
Michele Carbone Erin G. Flores Mitsuru Emi Todd A. Johnson Tatsuhiko Tsunoda Dusty Behner Harriet Hoffman Mary Hesdorffer Masaki Nasu Andrea Napolitano Amy Powers Michael Minaai Francine Baumann Peter Bryant-Greenwood Olivia Lauk Michaela B. Kirschner Walter Weder Isabelle Opitz Harvey I. Pass Giovanni Gaudino Sandra Pastorino Haining Yang 《PLoS genetics》2015,11(12)
We recently discovered an inherited cancer syndrome caused by BRCA1-Associated Protein 1 (BAP1) germline mutations, with high incidence of mesothelioma, uveal melanoma and other cancers and very high penetrance by age 55. To identify families with the BAP1 cancer syndrome, we screened patients with family histories of multiple mesotheliomas and melanomas and/or multiple cancers. We identified four families that shared an identical BAP1 mutation: they lived across the US and did not appear to be related. By combining family histories, molecular genetics, and genealogical approaches, we uncovered a BAP1 cancer syndrome kindred of ~80,000 descendants with a core of 106 individuals, whose members descend from a couple born in Germany in the early 1700s who immigrated to North America. Their descendants spread throughout the country with mutation carriers affected by multiple malignancies. Our data show that, once a proband is identified, extended analyses of these kindreds, using genomic and genealogical studies to identify the most recent common ancestor, allow investigators to uncover additional branches of the family that may carry BAP1 mutations. Using this knowledge, we have identified new branches of this family carrying BAP1 mutations. We have also implemented early-detection strategies that help identify cancers at early-stage, when they can be cured (melanomas) or are more susceptible to therapy (MM and other malignancies). 相似文献
108.
109.
Elena Grossini Kevin Bellofatto Serena Farruggio Lorenzo Sigaudo Patrizia Marotta Giulia Raina Veronica De Giuli David Mary Piero Pollesello Rosalba Minisini Mario Pirisi Giovanni Vacca 《PloS one》2015,10(4)
Background
Levosimendan protects rat liver against peroxidative injuries through mechanisms related to nitric oxide (NO) production and mitochondrial ATP-dependent K (mitoKATP) channels opening. However, whether levosimendan could modulate the cross-talk between apoptosis and autophagy in the liver is still a matter of debate. Thus, the aim of this study was to examine the role of levosimendan as a modulator of the apoptosis/autophagy interplay in liver cells subjected to peroxidation and the related involvement of NO and mitoKATP.Methods and Findings
In primary rat hepatocytes that have been subjected to oxidative stress, Western blot was performed to examine endothelial and inducible NO synthase isoforms (eNOS, iNOS) activation, apoptosis/autophagy and survival signalling detection in response to levosimendan. In addition, NO release, cell viability, mitochondrial membrane potential and mitochondrial permeability transition pore opening (MPTP) were examined through specific dyes. Some of those evaluations were also performed in human hepatic stellate cells (HSC). Pre-treatment of hepatocytes with levosimendan dose-dependently counteracted the injuries caused by oxidative stress and reduced NO release by modulating eNOS/iNOS activation. In hepatocytes, while the autophagic inhibition reduced the effects of levosimendan, after the pan-caspases inhibition, cell survival and autophagy in response to levosimendan were increased. Finally, all protective effects were prevented by both mitoKATP channels inhibition and NOS blocking. In HSC, levosimendan was able to modulate the oxidative balance and inhibit autophagy without improving cell viability and apoptosis.Conclusions
Levosimendan protects hepatocytes against oxidative injuries by autophagic-dependent inhibition of apoptosis and the activation of survival signalling. Such effects would involve mitoKATP channels opening and the modulation of NO release by the different NOS isoforms. In HSC, levosimendan would also play a role in cell activation and possible evolution toward fibrosis. These findings highlight the potential of levosimendan as a therapeutic agent for the treatment or prevention of liver ischemia/reperfusion injuries. 相似文献110.
Serena P. Koenig Alexandra Bornstein Karine Severe Elizabeth Fox Jessy G. Dévieux Patrice Severe Patrice Joseph Adias Marcelin Dgndy Alexandre Bright Ngoc Pham Pierre Cremieux Jean William Pape 《PloS one》2015,10(11)